Food News and Research

RSS

QIAGEN receives CE conformity marking for careHPV Test

QIAGEN has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries, the company announced today at the International Papillomavirus Conference in Montreal, Canada. The CE conformity marking ("Conformite Europeenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark.

From QIAGEN Manchester Limited 7 Jul 2010

FDA approves IMT to improve vision in patients with end-stage AMD

The U.S. Food and Drug Administration today announced it has approved the Implantable Miniature Telescope to improve vision in some patients with end-stage age-related macular degeneration.

7 Jul 2010

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.

7 Jul 2010

Lancet study series examines health in the Gaza Strip

Reuters reports on a series of studies published Friday in the Lancet, which examine the health of populations living in the Gaza Strip. The studies, which examined the effects of the violence on the region, conclude that Israel's blockade of the territory could "cause long-term damage to Palestinians' health, with many children at risk of stunted growth or malnutrition."

7 Jul 2010

PhyloTech closes $1.2M Seed financing round

PhyloTech, Inc., announced today it closed a $1.2 M Seed financing round in June. The Company provides analysis of over 50,000 bacterial and archaeal taxa in samples from any source to solve problems in human health, environmental damages assessment, bioremediation, recreational water quality, drinking water and food safety, and an array of other applications.

7 Jul 2010

Caraco Pharmaceutical Laboratories commences shipping azelastine ophthalmic solution

Caraco Pharmaceutical Laboratories, Ltd. has started shipping azelastine ophthalmic solution, 0.05%. This product was recently approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA).

7 Jul 2010

FDA approves Glassia for treating Alpha 1 deficiency

Kamada, today announced that the United States Food and Drug Administration has approved Glassia (Alpha 1 Proteinase inhibitor, also known as Alpha-1-Antitrypsin) for the treatment of Alpha 1 deficiency. GlassiaM is now the first and only liquid Alpha- 1-Proteinase Inhibitor worldwide available liquid, ready to use, Alpha- 1-Proteinase Inhibitor on the market.

7 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

Scientists discover nanoparticle to deliver DNA with minimum toxic effect

In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.

7 Jul 2010

PI3 kinase boosts body heat, helps burn excess calories

New findings by UT Southwestern Medical Center researchers suggest that an enzyme in the brain known as PI3 kinase might control the increased generation of body heat that helps burn off excess calories after eating a high-fat meal.

7 Jul 2010

Alcon signs definitive agreement to acquire LenSx Lasers

Alcon, Inc. announced today that it has entered into a definitive agreement to acquire LenSx Lasers, Inc, a privately held company that developed the first femtosecond laser to receive U.S. Food and Drug Administration clearance for use as a part of cataract surgery. The LenSx system is indicated for anterior capsulotomy and laser phacofragmentation during cataract surgery, providing a complementary surgical approach to certain manual steps within the traditional cataract procedure.

7 Jul 2010

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

Angion Biomedica Corp., a biopharmaceutical company dedicated to the discovery and development of novel therapeutics that enhance quality of life, eradicate disease and save lives by modulating the body's protective, reparative and regenerative systems, announced today that its lead therapeutic BB3 was accepted into the Fast Track program of the U.S. Food and Drug Administration (FDA) and has also been designated an Orphan Drug product by FDA.

7 Jul 2010

POMC neurons suppress appetite, induce weight loss: Research

A protein found in cells throughout the body must be present in a specific set of neurons in the brain to prevent weight gain after chronic feeding on high-calorie meals, new findings from UT Southwestern Medical Center researchers suggest.

7 Jul 2010

Three Rivers Pharmaceuticals receives FDA expanded labeling for INFERGEN

Three Rivers Pharmaceuticals, LLC, today received expanded labeling from the U.S. Food and Drug Administration (FDA) to include daily use of INFERGEN (Consensus Interferon) in combination with ribavirin (RBV) for retreatment of chronic hepatitis C patients. The expanded labeling targets hepatitis C patients who need retreatment.

6 Jul 2010

Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published

Sangamo BioSciences, Inc. announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.

6 Jul 2010

Epworth Manor celebrates 90 years of community care on July 8, 2010

From its humble beginnings in 1919 as a home for 14 residents, to the now seven-acre campus housing and caring for up to 172 seniors, Epworth Manor will be celebrating 90 years of being part of the Tyrone and central Pennsylvania community. An outdoor celebration will take place on July 8, from 5:30 p.m. to 7:30 p.m. and will include a big band concert by the Hallmark's, refreshments, photographs and memorabilia. The celebration will take place on the Epworth campus located at 951 Washington Ave., Tyrone, Pa.

6 Jul 2010

EMA completes validation process for Dyax's ecallantide MAA

Dyax Corp. announced today that the European Medicines Agency (EMA) has completed its validation process for the Marketing Authorization Application (MAA) for potential approval to market DX-88 (ecallantide) in the European Union (EU).

6 Jul 2010

Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study

Adeona Pharmaceuticals, Inc., announced today that on July 6, 2010, it completed an equity financing of $1 million with a single institutional investor, Seaside 88, L.P. The financing involved the sale of 1,212,121 registered shares of common stock and no warrants. Enclave Capital served as placement agent and will receive a 7% cash commission and 5-year warrants to acquire 60,606 shares of Adeona at $1.32 per share. The use of proceeds is intended for general corporate purposes.

6 Jul 2010

Children see more fast food TV ads and fewer sweets and beverage ads: Study

Children saw fewer television advertisements for certain foods, including those for sweets and beverages, in 2007 compared with 2003, according to a report posted online today that will appear in the September print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals. However, children now see more fast-food ads, and racial gaps in exposure to all food advertising have increased.

6 Jul 2010

APP receives FDA marketing clearance for preservative-free Heparin Lock Flush Solution

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market preservative-free Heparin Lock Flush Solution, USP in two dosage strengths, 10 USP Units/1 mL and 100 USP Units/1 mL, and will soon launch these single dose vial presentations.

6 Jul 2010